Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).
|Headquarters||Suite 3200, 1301 2nd Avenue|
SEATTLE, WA, United States 98101
|Chairman of the Board, President, Chief Executive Officer||John Johnson|
|Chief Financial Officer, Executive Vice President, Treasurer||Gregory Schiffman|
|Executive Vice President - Corporate Development, General Counsel, Secretary||Christine Cvijic|
|Executive Vice President - Human Resources||Gregory Mayes|
|Executive Vice President - Commercial Operations||Joseph DePinto|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||157.6M||Book Value||$0.22|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||2.1|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-99.00%|
*GAAP = prior to non-GAAP analyst adjusted earnings.